Pembrolizumab Plus Chemotherapy Per PD-L1 Stratum In Patients With Metastatic Non–Small Cell Lung Cancer: Real-World Effectiveness Versus Trial Efficacy

Abstract

No significant EE gap was found for pembrolizumab plus chemotherapy, except in the stratum nonsquamous mNSCLC with <1% PD-L1 tumor expression. In these patients, the survival in real-world was considerably shorter compared to the clinical trial results. Further studies are needed to determine which patient, treatment and or context factors contribute to this disparity.